Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 240 across all filing types
Latest filing 2024-07-05 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 June 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, and confirms compliance with listing rules. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, focusing on share capital and share movements rather than financial performance or management commentary. The document is about share capital and share movements, not a financial report, earnings release, or management discussion. It fits best under 'Share Issue/Capital Change' (SHA) as it reports on share capital and share movements. The document length (8053 characters) and detailed content confirm it is not a brief announcement or certification but a substantive report on share capital movements.
2024-07-05 English
POLL RESULTS OF THE 2023 ANNUAL GENERAL MEETING HELD ON JUNE 19, 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results from the 2023 Annual General Meeting (AGM) held on June 19, 2024. It details the voting outcomes on various resolutions including approval of the annual report, financial accounts, profit distribution plan, auditor re-appointment, and a general mandate for share issuance. The document does not contain the full annual report or financial statements but reports the results of shareholder voting at the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length (6129 characters) and content confirm it is not the full report but an announcement of voting results. Therefore, the correct classification is DVA with high confidence.
2024-06-19 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return on movements in securities for Lepu Biopharma Co., Ltd., including changes in authorised/registered share capital, issued shares, and confirmations related to share issues. It is addressed to the Hong Kong Exchanges and Clearing Limited and references specific listing rules (Chapter 19B, Main Board Rule 13.25A / GEM Rule 17.27A). The content focuses on share capital changes, share issuance, and confirmations of compliance with listing requirements. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is regulatory in nature, reporting share capital movements and confirmations to the exchange, which fits the category of Share Issue/Capital Change announcements rather than a full financial report or other categories. The length (8488 characters) and detailed tabular data support it being a substantive regulatory filing on share capital changes, not merely an announcement of a report. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2024-06-06 English
Proxy Form for the Annual General Meeting to be held on June 19 2024
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a proxy form for the Annual General Meeting (AGM) of Lepu Biopharma Co., Ltd. It includes instructions for shareholders to appoint proxies to vote on resolutions at the AGM, including approval of the annual report, financial accounts, profit distribution plan, auditor re-appointment, and other matters. The document is procedural and related to voting arrangements for the AGM, not the actual AGM materials or reports themselves. It is not a full report or presentation but a form for shareholders to participate in the AGM voting process. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). Since it is a proxy form used to solicit votes for the AGM, the correct classification is Proxy Solicitation & Information Statement (PSI).
2024-05-28 English
(1) 2023 REPORT OF THE BOARD OF DIRECTORS (2) 2023 REPORT OF THE BOARD OF SUPERVISORS (3) 2023 ANNUAL REPORT (4) 2023 FINANCIAL ACCOUNTS REPORT (5) 2024 FINANCIAL BUDGET (6) 2023 ANNUAL PROFIT DISTRIB
AGM Information Classification · 95% confidence The document is a circular containing the notice of the 2023 Annual General Meeting (AGM) of Lepu Biopharma Co., Ltd. It includes detailed information about the AGM agenda, including the consideration and approval of the 2023 Annual Report, reports of the Board of Directors and Supervisors, financial accounts report, financial budget, profit distribution plan, re-appointment of auditor, and a general mandate to issue additional shares. The document also contains the form of proxy and instructions for shareholders to vote. The text explicitly states it is a notice convening the AGM and provides information necessary for shareholders to make informed decisions at the meeting. It does not contain the full annual report or financial statements themselves but refers to them as being set out in the 2023 Annual Report published elsewhere. The document is lengthy (15,000 characters) and detailed but is primarily a meeting notice and related explanatory circular. Therefore, it fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including notices and circulars related to the meeting.
2024-05-28 English
NOTICE OF THE 2023 ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a formal notice for the 2023 Annual General Meeting (AGM) of Lepu Biopharma Co., Ltd. It includes details about the meeting date, location, agenda items such as approval of the annual report, financial accounts, profit distribution plan, and re-appointment of auditors. It also mentions procedural notes about voting and proxy appointments. The document does not contain the actual annual report or financial statements but serves as an invitation and agenda for the AGM. Therefore, it fits the category of AGM Information (AGM-R). The document length (5943 characters) supports it being a notice rather than a full report.
2024-05-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.